Business Context and Reporting Period
Akari Therapeutics plc filed this Form 8-K to report a September 29, 2026 amendment to CEO Abizer Gaslightwala’s employment agreement. The report concerns executive compensation, not operating results for a financial reporting period.
Key Financial and Compensation Terms
- Annual base salary increased from $475,000 to $625,000, effective August 18, 2026.
- During the 12 months beginning August 18, 2026, 10% of base salary—$62,500 in total—is to be delivered as restricted stock units (RSUs) instead of cash. The RSUs vest in quarterly installments, subject to the stated conditions.
- Target annual bonus opportunity increased from 50% to 55% of base salary. The company states target annual base salary and bonus compensation is approximately $970,000.
- Gaslightwala was granted options to purchase 174,000 American Depositary Shares (ADSs), vesting monthly over four years, with vesting deemed to begin March 18, 2026.
- The filing provides no revenue, profit, cash flow, margin, debt, or liquidity figures.
Material Changes, Conditions, and Risks
The amendment increases both the CEO’s base salary and target bonus opportunity and adds an option award. Issuance of the RSUs and options is subject to shareholder approval of an amendment to the 2023 Equity Incentive Plan to increase the ADSs reserved for issuance. If approval is not obtained, the RSUs will be forfeited and cancelled, and the company will make adjustment payments to ensure the CEO receives full base salary for the applicable period. The option grant is also subject to approval.
The filing provides no business outlook, financial guidance, or management commentary on operating performance. It refers readers to the full amendment filed as Exhibit 10.1 for complete terms.
Important Facts for Investors to Verify
- Whether shareholders approve the proposed increase in ADSs reserved under the 2023 Plan.
- The final treatment and value of the RSUs, including any adjustment payments if approval is not obtained.
- The complete vesting and other terms of the 174,000-ADS option grant in Exhibit 10.1.
- The potential dilution associated with the equity awards and any increase to the plan’s share reserve.